إسرائيل - الإنجليزية - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin - film coated tablets - empagliflozin 25 mg - linagliptin and empagliflozin - jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

كينيا - الإنجليزية - Pharmacy and Poisons Board

q pharma dmcc unit no: 2681 dmcc business centre level no - empagliflozin - tablet - empagliflozin 25mg - empagliflozin

كينيا - الإنجليزية - Pharmacy and Poisons Board

empagliflozin & linagliptin - tablet - empagliflozin 25 mg & linagliptin 5 mg - empagliflozin

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

cardinal health 107, llc - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u) - empagliflozin 10 mg - jardiance is indicated: limitations of use risk summary based on animal data showing adverse renal effects, jardiance is not recommended during the second and third trimesters of pregnancy. the limited available data with jardiance in pregnant women are not sufficient to determine a drug-associated risk for major birth defects and miscarriage. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see clinical considerations] . in animal studies, adverse renal changes were observed in rats when empagliflozin was administered during a period of renal development corresponding to the late second and third trimesters of human pregnancy. doses approximately 13-times the maximum clinical dose caused renal pelvic and tubule dilatations that were reversible [see data] . the estimated background risk of major birth defects is 6% to 10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20% to 25% in women with hba1c >10. the estimat

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - empagliflozin, quantity: 10 mg; linagliptin, quantity: 5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; macrogol 6000; hypromellose; crospovidone; maize starch; titanium dioxide; mannitol; purified talc; pregelatinised maize starch; copovidone; magnesium stearate - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).

كينيا - الإنجليزية - Pharmacy and Poisons Board

boeheringer ingelheim binger strasse 173 55216 ingelheim am rhein - empagliflozin - film-coated tablet - 25mg empagliflozin/tablet - drugs used in diabetes

الأردن - الإنجليزية - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة الأردنية السويدية - jordan sweden medical & sterilization co. - empagliflozin 25 mg/1 tab - 25 mg/1 tab

الأردن - الإنجليزية - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة مستودع الادوية العربي - the arab drug store p.s.c - empagliflozin 25 mg - 25 mg

كينيا - الإنجليزية - Pharmacy and Poisons Board

empagliflozin + linagliptin - film-coated tablet - 25mg empagliflozin + 5mg linagliptin /tablet - linagliptin and empagliflozin

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u) - empagliflozin 10 mg - jardiance is indicated: - to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. - to reduce the risk of sustained decline in egfr, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. - to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. - as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. limitations of use jardiance is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.1)] . jardiance is not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an egfr less than 30 ml/min/1.73 m2 . jardiance is likely to be ineffective in t